Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03086369 · ClinicalTrials.gov registry record · Phase 1
A Study of Nab-Paclitaxel and Gemcitabine With or Without Olaratumab (LY3012207) in Participants With Metastatic Pancreatic Cancer
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 184
- Enrollment target
NCT03086369 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 184 participants.
The verdict
NCT03086369, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 184 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety and efficacy of nab-paclitaxel and gemcitabine with or without olaratumab in the treatment of first-line metastatic pancreatic cancer.
Interventions
- DRUG Placebo
- DRUG Gemcitabine
- DRUG Nab-paclitaxel
- DRUG Olaratumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 184 participants |
| Start Date | 2017-06-22 |
| Est. Completion | 2021-06-17 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03086369
The ClinicalTrials.gov registry entry for NCT03086369 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 184 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT03086369 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03086369 about?
NCT03086369 is a clinical study titled "A Study of Nab-Paclitaxel and Gemcitabine With or Without Olaratumab (LY3012207) in Participants With Metastatic Pancreatic Cancer". The purpose of this study is to determine the safety and efficacy of nab-paclitaxel and gemcitabine with or without olaratumab in the treatment of first-line metastatic pancreatic cancer.
What is the current status of trial NCT03086369?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 184 participants. The study started on 2017-06-22. Estimated completion is 2021-06-17.
What interventions are being tested in trial NCT03086369?
The interventions under investigation include: Placebo (DRUG), Gemcitabine (DRUG), Nab-paclitaxel (DRUG), Olaratumab (DRUG).
Who is sponsoring clinical trial NCT03086369?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.